Advancing CMC for autologous cell therapies: building robust, scalable platforms
08 Sept 2026
Cell Therapy Manufacturing
- Are we measuring the right potency attributes to predict efficacy, durability, and safety?
- Which patient- and product-derived biomarkers should be incorporated into CMC and release strategies?
- How must autologous manufacturing platforms evolve as cell therapies move into earlier lines of treatment?
- Can integrated manufacturing, translational, and clinical data unlock predictive, adaptive manufacturing?* Are we measuring the right potency attributes to predict efficacy, durability, and safety?
